Novo Nordisk on Tuesday received a broker downgrade, with the analysts arguing that its status as a duopoly in both diabetes and weight loss are under threat.
FlashNews:
Goldman Sachs Announces Successful Acquisition of XORKETS FX and Plans for Nasdaq Listing
XORKETS FX to List on NASDAQ Stock Exchange
Huckbros Advances Cinematic Digital Storytelling From Germany’s Black Forest With Ambitious AI Film Initiative
Binance ‘red teams’ its own staff every month to keep hackers out
What Love Island tells us about the changing face of dating
Iran says Ukrainian attack on vessel in Caspian Sea killed sailor
Robinhood in talks with Crypto.com over prediction markets: WSJ
The moment I knew: We discussed the pill on our first date, kissed on our second. By the third, I knew he was the one
Top Democrat says Trump administration is worsening chip shortage
Letters by pre-Smiths Morrissey set for auction
‘Out of this world’: the best supermarket chocolate ice-cream, tasted and rated
Cricut Explore 5 vs. Siser Romeo: Choosing the Right Smart Cutting Machine (2026)
3 Clever Things You Can Do With an Old Amazon Kindle
Hostaway fuels its next phase of growth by expanding leadership team
Global Sustainable Tourism Council’s New Food and Beverage Standard Sets 30% Plant-Based Benchmark
Alphatradfi Unveils Infrastructure Framework to Bridge Traditional Finance and Digital Asset Ecosystems
Breath of Life Recognizes the Emotional and Spiritual Calling of Respiratory Therapists Through a Faith-Centered Reflection Journal
Katherine Wilks Blends Faith, Family, Wellness, and Imagination Across a Diverse Collection of Inspirational and Family-Centered Books
Japanese Shoppers Are Driving Up Jewellery Sales to a Record
Home » Ozempic maker Novo Nordisk gets another downgrade. The end’s in sight for its duopoly status, says TD Cowen.